Business
BNB Plus describes itself as a digital-asset treasury company that adopted BNB as its primary reserve asset while retaining LineaRx synthetic nucleic-acid production solutions.
BNB Plus is a BNB digital-asset treasury pivot with a LineaRx synthetic-DNA business, restructuring, no insider flow, and a larger FY2025 loss.
The read at a glance✓ Audited against SEC data
- Business mix — BNB treasury plus LineaRxNote
- Revenue rows — No consolidated sales tagWatch
- Segment sales — DNA segments near $2.1MNote
- Loss — Net loss $15.2MWatch
- Equity — $2.3M, -74.8%Watch
- Insiders — 0 purchases / 0 salesNote
- Accounting — Forensic screens unavailableNote
Where the revenue comes from
Fiscal 2025, as BNB PLUS CORP. reports it. History and quarterly detail are in the app.
- DNA Tagging and Security Products$1.1M
- Therapeutic DNA Production$988K
Leadership changes
From BNB PLUS CORP.'s own filings, the day they're filed.
- James Haft · director · departureeff. 2026-02-02
- Schmalz Shaheen · director · departureeff. 2026-02-02
- Elizabeth M. Schmalz Shaheen · director · departureeff. 2026-01-15
Latest filings
- 8-K · Company announcement2026-09-03
- 10-Q · Quarterly report2026-08-13
- 8-K · Company announcement2026-07-29
- 8-K · Company announcement2026-07-13
- 8-K · Company announcement2026-07-02
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- Main tension🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about BNB PLUS CORP., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.